in a large community-based cohort, and compared its clinical characteristics with those of OSA. Baseline data from 5,804 participants in the Sleep Heart Health study were reviewed. 0.9% and 0.4% of participants were found to have CSA and Cheyne Stokes respiration (CSR), respectively. Those with CSA were older, had lower body mass index, lower Epworth Sleepiness Scale scores, and were more likely to be male than those with OSA. In patients with self-reported heart failure, OSA was more common than CSA (55.1% vs 4.1%).
Comment (AN):
A New Zealand study by Kathy Ferrier of stable heart failure patients living in the community also showed that OSA is more common than CSA/CSR (53% vs 15%). The most important drivers were severity of heart failure, presence of atrial fibrillation and levels of obesity.
Reference: Sleep 2016;39(7):1353-59 Abstract
Maternal sleep-disordered breathing and the risk of delivering small for gestational age infants
Authors: Pamidi S et al.
Summary: This prospective cohort study evaluated whether SDB in the third trimester is associated with the delivery of small for gestational age (SGA) infants. 234 participants in a multicentre pregnancy cohort study were evaluated in the third trimester for SDB based on symptoms and PSG. 27 (12%) participants delivered an SGA infant. SDB symptoms (snoring and/or witnessed apnoeas) in the third trimester had a potential but not statistically significant association with delivering an SGA infant. However, the odds of delivering an SGA infant were significantly increased with PSG-based diagnosis of maternal SDB (odds ratio, 2.65; p=0.02).
Comment (AN): OSA (AHI >10) was common (1/3) in the third trimester but due to adaptive changes in respiratory drive, arousal responses and presumably upper airway tone did not result in desaturation. The investigators found an increased risk of delivering small for gestational age infants with maternal SDB determined by PSG and recommend clinical trials to test whether treatment of SDB in pregnancy improves the lifelong health of the newborn infant. 
Comment (AN):
This meta-analysis examines the evidence for pharmacological treatment (with modafinil or the still in-patent isomer armodafinil) of residual sleepiness in CPAP-treated OSA. Modafinil is not available for this indication in New Zealand unless there is an additional diagnosis of narcolepsy. Although well tolerated I have concerns about adherence (drop-outs) and there were no comparative studies with less expensive central nervous system stimulants.
Reference: Sleep Med Rev 2015;30:97-107 Abstract
Support your patients with Asthma and COPD booklets including Management Plans for your practice.
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Sleep Medicine Research Review a publication
Sexsomnia: a specialized non-REM parasomnia?
Authors: Dubessy A et al.
Summary: This study examined the clinical characteristics of patients with sexsomnia compared with healthy controls and sleepwalkers. Individuals referred for sexsomnia, sleepwalking and night terrors were interviewed and assessed using the Paris Arousal Disorder Severity Scale (PADSS). They were also monitored by video-PSG for up to 2 nights. Seventeen patients (70.6% male) were found to have sexsomnia, and their sexual behaviours were more direct during sleep than during wakefulness. Patients with sexsomnia had more N3 awakenings than matched controls and the same amount as regular sleepwalkers.
Half of them presented evidence of cortico-cortical dissociation, including concomitant slow (mostly frontal) and rapid (mostly temporal and occipital) EEG rhythms. Of 89 sleepwalkers, 10% had previous episodes of amnestic sexual behaviour.
Comment (AN):
The paper reports clinical, polysomnographic features and forensic consequences of sexsomnia -a prior history of sleepwalking and PSG features may prove helpful in evaluation. Concomitant OSA should always be carefully looked for as a reversible cause of arousal from sleep that can reduce parasomnia occurrence.
Reference: Sleep 2016; published online Oct 28 Abstract
Cognitive-behavior therapy singly and combined with medication for persistent insomnia: impact on psychological and daytime functioning
Authors: Morin C et al.
Summary:
This study evaluated the impact of CBT, alone and combined with medication, on various indices of daytime and psychological functioning in adults with chronic insomnia. 160 patients with chronic insomnia were given CBT alone or with medication (zolpidem) for an initial 6-week period, followed by an extended 6-month period. After the initial 6-week treatment period, significant improvements of fatigue, quality of life (mental component), anxiety, and depression were seen in the CBT alone group but not in the CBT + medication group. Improvements were well maintained at the 6-month follow-up.
Comment (KF):
This group previously published results of the sleep outcomes in the same study which showed that CBT alone and CBT combined with medication produced similar improvements in nighttime sleep after the 6-week acute treatment phase. Bearing in mind that patients mostly seek treatment for insomnia due to the daytime effects (e.g. fatigue, mood symptoms), my take away points from this very useful additional study were: 1) that following acute treatment (six weekly 90 minute group sessions), significant improvements of fatigue, quality of life (mental component), anxiety, and depression were obtained in the CBTi alone condition but not in the combined CBTi plus medication condition; and 2) that maintenance CBTi (e.g. monthly for 6 months) leads to additional improvements in psychological well-being, fatigue, and quality of life. Effect of a web-based cognitive behavior therapy for insomnia intervention with 1-year follow-up
Authors: Ritterband L et al.
Summary:
This study evaluated the use of a web-based CBTi intervention in adults with chronic insomnia. 303 adults were randomised to undergo an internet CBTi programme or receive online patient education. The internet CBTi (Sleep Healthy Using the Internet [SHUTi]) was a 6-week fully automated, interactive, and tailored web-based programme that incorporated the primary tenets of face-to-face CBTi.
Patients in the patient-education group received nontailored and fixed online information about insomnia. Outcomes were significantly in favour of the CBTi group for Insomnia Severity Index, sleep-onset latency, and wake after sleep onset during follow up, and treatment effects were maintained at 1-year. 56.6% of patients in the CBTi group achieved remission status and 69.7% were deemed treatment responders at 1 year based on Insomnia Severity Index data.
Comment (KF):
Internet-based CBTi is a promising option to achieve improved sleep outcomes in those with chronic insomnia. It may help to address the issues of access and affordability that hinder the widespread use of CBTi to treat insomnia. However, it does still come with a cost (SHUTi costs approximately $190 for 16-week access) and won't be acceptable to all. It is important also to remember that the participants in this particular trial were predominantly female, white, highly educated and comfortable with internet use. The accompanying editorial to this article reminds us that restraint is called for -the study was essentially unblinded so the true effect size (SHUTi vs control) remains unknown and all internet CBTi programmes are not equal. It is also important to remember that individual behavioural components of CBTi given in the primary care setting can be effective (improving the access and affordability of insomnia treatment). An example is sleep scheduling (sleep restriction) advice which has been shown to lead to significant improvements in sleep quality and fatigue at 6 months for those with chronic primary insomnia (Simplified sleep restriction for insomnia in general practice: a randomised controlled trial. Br J Gen Pract 2015).
Reference: JAMA Psychiatry 2016; published online Nov 30 Abstract
Short-and long-term effects of CBT-I in groups for school-age children suffering from chronic insomnia: the KiSS-Program Authors: Schlarb A et al.
Summary:
This study evaluated the short-and long-term effects of CBTi (the KiSS-Program) in school-age children with chronic insomnia. 112 children with chronic insomnia were randomly assigned to a wait-list control group or to the KiSSprogram (3 sessions for the children and 3 sessions for their parents). Children who received CBTi reported greater improvements in sleep behaviour immediately after treatment compared to the control group. Improvements persisted at the 3-, 6-, and 12-month follow-up assessments.
Comment (KF):
This study showed improved sleep (compared to wait-list control) over the 6-week treatment period. Education and strategies were given to both children and parents. Therapy puppet Kalimba (a leopard with magical spots for good sleep) also helped introduce and reinforce concepts. The treatment seems quite intensive with multiple strategies. It would be great to know which of these might be the more magical ingredients (apart from the leopard's spots) so that the treatment could be replicated more easily. Sleep improvements were maintained over the long follow up but there was no control group (after the 6-week period) for comparison so the true long term effect of the CBTi is unclear. A similar study in children with mental disorders or attention deficit hyperactivity disorder would be valuable.
Reference: Behav Sleep Med 2016:1-21 Abstract
Obesity may be the common pathway for sleep-disordered breathing in women with polycystic ovary syndrome Authors: Suri J et al.
Summary:
This case-control study in India investigated the cause of the increased prevalence of SDB in women with polycystic ovary syndrome (PCOS). 50 cases with untreated PCOS were compared with 100 controls. 66% of cases and 4% of controls had SDB (odds ratio, 46.5; p<0.001). After adjustment for body mass index (BMI) and waist circumference, the betweengroup difference was not significant. Free testosterone levels were significantly higher in the PCOS group than in controls (p<0.001).
Comment (KF):
Increased testosterone predisposes to central obesity presumably leading to increased risk of SDB in this PCOS group. Obesity in these Indian women was defined as BMI>25 so it is important not to overlook our Indian women patients in the BMI 26-30 range (rather than just considering obesity to be BMI>30). It was interesting to note that there was notable under-reporting of snoring so there is a real drawback in using this as a surrogate marker of risk for SDB (in Indian women at least). The other notable point from this study is that the women were relatively youngish. So perhaps be mindful of the young Indian patient with PCOS who does not look obviously obese and doesn't snore as she may still have SDB.
Reference: Sleep Med 2016;24:32-39 Abstract
Prevalence and predictors of obstructive sleep apnoea in young children with Down syndrome
Authors: Hill C et al.
Summary: This study examined the prevalence and predictors of OSA in children with Down syndrome. 202 children with Down syndrome aged from 6 months to <6 years were recruited; 188 out of 202 (93%) children were successfully evaluated. 59% of them were found to have mild to moderate OSA and 14% had moderate to severe OSA. Male sex and habitual snoring predicted OSA, whereas age, body mass index and tonsillar size did not.
Comment (KF):
It is very important to appreciate the high prevalence of OSA in young children with Down syndrome and to ensure this population is routinely screened. Importantly, body mass index and tonsillar size did not predict OSA so objective screening is required. Recognition and treatment of OSA is important to help ensure optimal cognitive functioning and quality of life. This study used domiciliary cardiorespiratory polygraphy as a more feasible alternative to polysomnography. 
